Detalles de la búsqueda
1.
Multiple myeloma.
Lancet
; 397(10272): 410-427, 2021 01 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-33516340
2.
Myeloma patients' experiences of a supervised physical activity programme: a qualitative study.
Support Care Cancer
; 30(7): 6273-6286, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35467117
3.
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive).
Haematologica
; 106(10): 2694-2706, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33910333
4.
Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design.
Br J Cancer
; 123(2): 187-195, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32435057
5.
Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy.
Br J Haematol
; 191(2): 194-206, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32678948
6.
BCMA CARs in multiple myeloma: room for more?
Blood
; 137(21): 2859-2860, 2021 05 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-34042980
7.
Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors.
Br J Haematol
; 196(3): e21-e26, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34632575
8.
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.
Br J Haematol
; 196(4): e33-e37, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34636043
9.
Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model.
Br J Haematol
; 172(1): 64-79, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26767468
10.
Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
Br J Haematol
; 174(6): 911-22, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27313079
11.
Development of antibody response to SARS-CoV-2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy.
Br J Haematol
; 194(5): 857-861, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34323287
12.
Response to 'Impact of immunosuppression on mortality in critically ill COVID-19 patients'.
Br J Haematol
; 191(3): 505-506, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33103782
13.
The importance of microsurgery in childhood meningioma: a case report.
Childs Nerv Syst
; 31(1): 161-5, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25034239
14.
Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials.
Br J Haematol
; 185(2): 344-347, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29978458
15.
Clinical benefit of depth of response for relapsed/refractory multiple myeloma patients treated on clinical trials: retrospective analysis from two tertiary centres.
Br J Haematol
; 186(1): 162-165, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30592025
16.
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
Br J Haematol
; 185(5): 948-951, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30460696
17.
More convenient proteasome inhibition for improved outcomes.
Lancet Oncol
; 19(7): 856-858, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29866476
18.
Deep Learning Enables Spatial Mapping of the Mosaic Microenvironment of Myeloma Bone Marrow Trephine Biopsies.
Cancer Res
; 84(3): 493-508, 2024 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37963212
19.
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Lancet Rheumatol
; 6(6): e339-e351, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38734019
20.
A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors.
BMC Cancer
; 13: 31, 2013 Jan 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-23347597